Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Fate Therapeutics (FATE)
NASDAQ:FATE
Holding FATE?
Track your performance easily
FATE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.63 - $8.83
Previous Close$3.84
Volume1.18M
Average Volume (3M)2.10M
Market Cap
$437.29M
Enterprise Value$232.97M
Total Cash (Recent Filing)$304.88M
Total Debt (Recent Filing)$100.56M
Price to Earnings (P/E)―
Beta2.70
Next Earnings
Oct 31, 2024EPS Estimate
-$0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.71
Shares Outstanding113,877,884
10 Day Avg. Volume1,557,036
30 Day Avg. Volume2,096,608
Standard Deviation0.24
R-Squared0.17
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.08
Price to Sales (P/S)34.86
Price to Cash Flow (P/CF)-3.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue18.91
Enterprise Value/Gross Profit3.67
Enterprise Value/Ebitda-1.44
Forecast
1Y Price Target
$5.78Price Target Upside50.52% Upside
Rating ConsensusHold
Number of Analyst Covering12
Fate Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThe first patient dosed with FT522 in a conditioning-free regimen for B-cell lymphoma experienced no significant adverse events, showcasing promising early safety.
Financial PerformanceFate Therapeutics ended the quarter with a cash position of approximately $352 million, expected to fund operations through the end of 2026.
RevenueFate Therapeutics recorded $6.8 million in collaboration revenue, surpassing the prior forecast of $5.0 million, indicating strong partnership performance.
Bears Say
Clinical EfficacyRisks include, but are not limited to: unknown clinical efficacy advantage with FT522 relative to other allogeneic and autologous CAR-T approaches.
Pipeline UpdatesA competitive profile with its iPSC derived programs seems far away, and analysts rate FATE Market Perform as they see limited opportunities for value generation in upcoming months.
Program HaltThe company announced the decision to halt development of its iPSC-derived CAR-T therapy FT819 in B-cell malignancies (BCM) and instead pursue further development exclusively in autoimmunity.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
FATE FAQ
What was Fate Therapeutics’s price range in the past 12 months?
Fate Therapeutics lowest stock price was $1.63 and its highest was $8.83 in the past 12 months.
What is Fate Therapeutics’s market cap?
Currently, no data Available
When is Fate Therapeutics’s upcoming earnings report date?
Fate Therapeutics’s upcoming earnings report date is Oct 31, 2024 which is in 68 days.
How were Fate Therapeutics’s earnings last quarter?
Fate Therapeutics released its earnings results on Aug 13, 2024. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.464 by $0.134.
Is Fate Therapeutics overvalued?
According to Wall Street analysts Fate Therapeutics’s price is currently Undervalued.
Does Fate Therapeutics pay dividends?
Fate Therapeutics does not currently pay dividends.
What is Fate Therapeutics’s EPS estimate?
Fate Therapeutics’s EPS estimate is -$0.42.
How many shares outstanding does Fate Therapeutics have?
Fate Therapeutics has 113,877,884 shares outstanding.
What happened to Fate Therapeutics’s price movement after its last earnings report?
Fate Therapeutics reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.464. Following the earnings report the stock price went down -2.096%.
Which hedge fund is a major shareholder of Fate Therapeutics?
Among the largest hedge funds holding Fate Therapeutics’s share is Deerfield Management Company, LP. It holds Fate Therapeutics’s shares valued at 12M.
---
Fate Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.78 (50.52% Upside)
$5.78 (50.52% Upside)
Blogger Sentiment
Bullish
FATE Sentiment 66%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 2.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 3.5%
Last 30 Days ▼ 3.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
41.69%
12-Months-Change
Fundamentals
Return on Equity
-42.10%
Trailing 12-Months
Asset Growth
-9.57%
Trailing 12-Months
Company Description
Fate Therapeutics
Fate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
---
FATE Earnings Call
Q1 2024
0:00 / 0:00
---
FATE Stock 12 Month Forecast
Average Price Target
$5.78
▲(50.52% Upside)
Technical Analysis
Adverum Biotechnologies
―
Crispr Therapeutics AG
―
Editas Medicine
―
Intellia Therapeutics
―
Best Analysts Covering FATE
1 Year
1 Year Success Rate
4/13 ratings generated profit
1 Year Average Return
-0.56%
reiterated a buy rating 11 days ago
Copying Peter Lawson's trades and holding each position for 1 Year would result in 30.77% of your transactions generating a profit, with an average return of -0.56% per trade.
---